FindTrial
Sign In

Placebo to match ondansetron

DRUG3 trials

Sponsors

Kartos Therapeutics Inc., Merck Sharp & Dohme LLC

Conditions

Advanced or Recurrent Endometrial CancerPost-operative NauseaPost-operative VomitingPrimary MyelofibrosisSecondary Myelofibrosis (including but not limited to myelofibrosis post-Polycythemia Vera or post-Essential Thrombocythemia)

Phase 2

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)
CompletedNCT01732458
Merck Sharp & Dohme LLCPost-operative Nausea, Post-operative Vomiting
Start: 2013-02-12End: 2016-09-26Updated: 2018-09-25
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
CompletedCTIS2022-502196-31-00
Kartos Therapeutics Inc.Advanced or Recurrent Endometrial Cancer
Start: 2023-08-21End: 2024-07-26Target: 140Updated: 2024-05-15

Phase 3

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingCTIS2023-504724-25-00
Kartos Therapeutics Inc.Primary Myelofibrosis, Secondary Myelofibrosis (including but not limited to myelofibrosis post-Polycythemia Vera or post-Essential Thrombocythemia)
Start: 2024-10-16Target: 126Updated: 2025-10-06

Related Papers

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
2026-03-07
Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects.
2018-09-219 citations